Why the study?
Clinical samples are routinely inactivated to prevent pathogen transmission, but the impact of inactivation on antibody-based cytokine and chemokine detectability has been overlooked.
Does sample inactivation using Triton X-100 or heat affect cytokine/chemokine detectability by ELISA in clinical samples?
Does sample inactivation using Triton X-100 or heat affect cytokine/chemokine detectability by ELISA in clinical samples?
Heat inactivation significantly reduces the detectability of certain cytokines and chemokines in plasma, whereas Triton X-100 has minimal impact, highlighting the need to select appropriate inactivation methods for accurate analysis.
This is the authors' abstract. We don't add key points for this paper.
Clinical samples are routinely inactivated before molecular assays to prevent pathogen transmission. Antibody-based assays are sensitive to changes in analyte conformation, but the impact of inactivation on the analyte detectability has been overlooked. This study assessed the effects of commonly used inactivation-methods, Triton X-100 (0.5%) and heat (60 °C, 1 h), on cytokine/chemokine detection in plasma, lung aspirates, and nasopharyngeal samples. Heat significantly reduced analyte detectability in plasma (IL-12p40, IL-15, IL-16, VEGF, IL-7, TNF-β) by 33-99% (p ≤ 0.02), while Triton X-100 minimally affected analytes in plasma and nasopharyngeal samples (11-37%, p ≤ 0.04) and had no significant impact on lung aspirates. Structural analysis revealed that cytokines affected by heat had more hydrophobic residues and higher instability-indices. As the protein-detectability was affected differently in different sample types, the sample environment could also influence protein stability. This underscores the importance of selecting the most suitable inactivation methods for clinical samples to ensure accurate cytokine/chemokine analysis in both clinical and research settings.
Answers are grounded in this paper and cite their sources.
May warrant Triton X-100 over heat for plasma cytokine assays; animal data leaves clinical validation open.
No takes yet. Share an insight, caveat, or question.
Labossiere et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: